Halda Therapeutics Receives FDA Fast Track Designation for HLD-0915 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Halda Therapeutics Receives FDA Fast Track Designation for HLD-0915 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Halda Therapeutics announced that the US FDA granted Fast Track designation to HLD-0915, the company’s lead development candidate, for the treatment of patients with mCRPC. [Halda Therapeutics] Press Release

HLD-0915 Receives FDA Fast Track Designation for mCRPC Treatment

FDA fast-tracks HLD-0915, a novel therapy for metastatic castration-resistant prostate cancer, promising rapid development and potential breakthrough treatment.